HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 26, Nos. 09 & 10, September & October 2022 – Toxins and Medicines – Two Sides of the Same Coin       » Utilising Metal Nanoparticles as Plant Growth Regulators to Improve Crop Yield       » Remedy or Poison? How Microplastics Influence Copper Ion Toxicity in Aquatic Plants       » Synthesising Schiff Base Antimicrobial Copper Complexes With Unprecedented Speed       » Enhancing the Understanding of Past Infections With Machine Learning       » Mini, Cellular Bioweapons: Understanding the Structure and Mechanism of Stinging in Sea Anemone Nematocysts       » Converting Dead Spiders Into Gripping Tools
Vol 19, No. 08, August 2015   |   Issue PDF view/purchase
SPOTLIGHTS
Sunitinib is an FDA-approved therapy used in palliative treatment for metastatic kidney cancer. This therapy is available in the market since 2005, and high toxicities was observed in both Singapore and other Asian cohorts at conventional dosing. Dr Tan Min Han, a visiting Consultant at Medical Oncology and Cancer Genetics National Cancer Centre Singapore (NCCS), provides further details on Long-term Outcomes of Attenuated Sunitinib Dosing in an Asian Population. This 10-mins interview was conducted by Rachel Lim.

Rachel: How was this study conducted?

Tan: This study was conducted as a prospective registry at the National Cancer Centre from 2007 onwards to current, after we observed severe toxicities in our patients using conventional dosing of sunitinib. The challenge was to balance our subjective observations against the demands of structured data required to lift our work to an experience that could be generalized regionally to improve cancer care Following dose-attenuation, outcomes were systematically compared against outcomes from parallel centres prescribing conventional dosing. The results were that our dose-attenuated regimen was equally efficacious, while being safer in terms of reduced side effects.

R: What are some of the reasons toxicities occur during the treatment of renal cancer?

Tan: Toxicities occur because of off-target effects by the therapy. Targeted therapies still may have scattershot or collateral damage, resulting in these drugs having effects on tissues other than the cancer cells. These side effects may include fatigue, hair discoloration, hypertension and skin rash.

R: What is the importance of these particular findings? How will this affect the treatment of renal cancer?

Tan: Our findings allow us to improve patient care using a targeted therapy for kidney cancer, achieving lower toxicities, with equivalent cancer survival outcomes. It would also be considerably cheaper for our patients, saving each patient about S$1300 per month in treatment costs. Our regimen is now established as current standard of care in Singapore, based on our clinical observations of intolerably high toxicities based on conventional dosing.

R: What is the difference in the dosing regimen in this study as compared to what is usually done?

Tan: Conventional textbook dosing of Sunitinib begins at 50 mg daily. Our recommended practice of reducing the starting dose to 37.5 mg has become conventional national practice in Singapore, as a direct result of this study, and to our knowledge, this practice is already growing in Asia. This work shows the benefit of real world experience for a new cancer therapy collated across multiple centres.

About the Interviewee

Dr. Tan Min-Han is a medical oncologist who divides time between the hospital and the laboratory. He sees patients as a visiting consultant medical oncologist at the National Cancer Centre Singapore (NCCS), specializing in urological cancers and clinical cancer genetics. He is also a principal investigator at the Institute of Bioengineering and Nanotechnology. He completed his medical oncology fellowship training at NCCS, and completed his PhD in the molecular epidemiology of kidney cancer. Dr Tan's research interests centre on practical cancer diagnostics, with a special interest in circulating biomarkers. He has contributed over 70 original papers and is an inventor of several novel technologies. Additionally, his public health research interests focus on optimisation of patient care through data-driven modelling of clinical outcomes in a wide range of cancers. Dr. Tan is the lead editor for the Singapore Cancer Network (SCAN), a national practice framework for Singapore oncologists.

FORTHCOMING ISSUE  
What Has Covid Ever Done for Us?
NEWS CRUNCH  
news 2022 PDA Aseptic Processing of Biopharmaceuticals Conference
news Thailand LAB INTERNATIONAL, Bio Asia Pacific, and FutureCHEM INTERNATIONAL are ready to offer the Science and Technology Industry complete solutions this September!
news Better together: registration opens for Vitafoods Asia 2022 co-located with Fi Asia in October
news 2022 PDA Pharmaceutical Manufacturing & Quality Conference
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   [email protected] or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   [email protected]
Copyright© 2022 World Scientific Publishing Co Pte Ltd  •  Privacy Policy